Which Stocks Had a Great Week and Which Didn’t Do So Well
One of the surest things in online stock trading is how the stock market changes its course over a period of time. As you’d expect, every week in the stock market has something memorable for some stocks, while for the others, it may not be worth remembering. The third week of July had its share of winners and losers. Let’s take a look at the happenings.
Emmaus Life Sciences, Inc ($EMMA) had the most memorable week, with a 39.63% growth to $9.80. The biopharm company has just completed its merger with MYnd Analytics. Understandably, it had a Buy rating on TradingView.com. Outlook Therapeutics ($OTLK) had a great week as well, soaring 34.87% to $2.63 with a Buy rating. Next was Regional Health Properties ($RHE) that grew 30.53% to $2.48 and was given a Buy rating. In the S&P 500, tobacco giant Philip Morris International, Inc ($PM) had an 8.22% growth to $87.71. KLA Corp ($KLAC) rose 6.31% to $133.4, while Union Pacific Corp ($UNP) soared 5.89% to $174.25. The railroad company experienced record Q2 financial results.
Eagle Bancorp, Inc ($EGBN) dropped 26.75% to $39.15, and had a Strong Sell rating. ADTRAN, Inc ($ADTN) was a Strong Sell after it sank 23.32% to $12.13. aTyr Pharma, Inc ($LIFE) dropped 22.49% to $4.17. Hovnanian Enterprises, Inc ($HOV) sank 18.65% to $6.98 for a Sell rating. In the S&P 500, Netflix, Inc ($NFLX) dropped 10.27% to $325.21. United Rentals, Inc ($URI) experienced a 7.89% decline to $121.11. Genuine Parts Co ($GPC) sank 4.51% to $97.61, while M&T Bank Corp ($MTB) declined 4.51% to $162.76. Keeping tabs on the markets is important for success in stock trading, as much as using advanced trading software is. Getting an insight into the week’s trading can help you, at least to some extent, in planning your future moves.
The content provided here is solely for informational and educational purposes and does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by TradeZero in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Investors are advised not to rely on the information contained in this writing to make an informed investment or financial decision. TradeZero explicitly disclaims all liability for any action taken based on any information contained in this writing.